Michel Dahan is COO & VP at Akebia Therapeutics, Inc. (AKBA). They have made 17 open-market trades across 1 company since 2016, most recently 2024-05-13.
CIK 0001669737
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 17 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AKBA | 672,092 | $451K |
Shares reported on the most recent Form 4, priced at the 2024-05-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKBA | SELL · 10b5-1 | 2024-05-13 | 2024-05-14 | $1.26 | $44K | -9.8% | -8.2% | +0.8% |
| AKBA | SELL | 2024-02-29 | 2024-03-01 | $1.58 | $14K | -20.3% | -7.9% | -39.0% |
| AKBA | SELL | 2024-02-27 | 2024-02-29 | $1.52 | $16K | -9.6% | +3.8% | -34.4% |
| AKBA | SELL | 2023-05-25 | 2023-05-25 | $1.22 | $233K | +5.8% | -24.8% | +6.6% |
| AKBA | SELL | 2023-03-01 | 2023-03-03 | $0.88 | $18K | -30.0% | -39.8% | +13.6% |
| AKBA | SELL | 2023-02-27 | 2023-03-01 | $0.81 | $8K | -12.2% | -34.8% | +11.5% |
| AKBA | SELL | 2022-02-28 | 2022-03-02 | $2.16 | $32K | -3.2% | -73.0% | -85.0% |
| AKBA | SELL | 2021-04-01 | 2021-04-01 | $3.40 | $4K | -7.3% | -5.4% | +12.8% |
| AKBA | SELL | 2021-03-01 | 2021-03-02 | $3.40 | $49K | +3.5% | -4.5% | -2.2% |
| AKBA | SELL | 2020-02-28 | 2020-03-02 | $8.70 | $121K | -33.2% | -26.6% | +22.9% |
| AKBA | SELL · 10b5-1 | 2017-10-02 | 2017-10-04 | $19.64 | $27K | -7.4% | -10.5% | -24.7% |
| AKBA | SELL | 2017-09-28 | 2017-10-02 | $19.30 | $97K | -1.3% | -8.5% | -23.3% |
| AKBA | SELL | 2017-08-15 | 2017-08-17 | $15.00 | $75K | +13.0% | +16.8% | -0.5% |
| AKBA | SELL | 2017-07-03 | 2017-07-06 | $14.26 | $20K | -6.0% | -9.9% | +32.7% |
| AKBA | SELL | 2017-04-03 | 2017-04-04 | $9.18 | $13K | +2.5% | +44.7% | +64.9% |
| AKBA | SELL | 2017-01-01 | 2017-01-03 | $10.49 | $17K | -6.3% | -9.0% | -15.5% |
| AKBA | SELL | 2016-10-01 | 2016-10-04 | $8.95 | $13K | -10.5% | -20.6% | +16.0% |
| AKBA | SELL | 2016-07-05 | 2016-07-06 | $7.47 | $10K | +5.2% | +9.7% | +11.6% |
| AKBA | SELL | 2016-04-04 | 2016-04-05 | $9.41 | $13K | +3.3% | -6.0% | -22.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.